Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT06966154
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of Relapsed/Refractory Natural Killer/T-Cell Lymphoma (NKTCL)
Sponsor: Fudan University
Interventions
Selinexor golidocitinib tislezumab
Updated 1 time since 2025 Last updated: May 26, 2025 Started: May 26, 2025 Primary completion: May 30, 2027 Completion: May 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Natural Killer/T-cell Lymphoma and Relapsed or Refractory Lymphoma Including ENKL, this trial is actively recruiting participants. The trial is conducted by Fudan University and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Fudan University
Data source: Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .